By Fineline Cube 
UK-based pharmaceutical firm AstraZeneca (AZ; NASDAQ: AZN) this week unveiled results from the Phase III KALOS and LOGOS trials for its inhalable combination Breztri Aerosphere (budesonide + glycopyrronium + formoterol fumarate) in uncontrolled asthma. The trials successfully met all primary endpoints, demonstrating statistically significant and clinically meaningful improvements in lung function compared to dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) therapies, with no new safety signals identified.
Breztri Aerosphere Overview
Breztri Aerosphere is a fixed-dose triple therapy currently approved in over 80 countries, including the US, EU, China, and Japan, for chronic obstructive pulmonary disease (COPD). The drug reported 2024 global sales of USD 978 million, reflecting a 44% year-on-year growth. The positive results from the KALOS and LOGOS trials further validate its potential as an effective treatment option for patients with uncontrolled asthma.-Fineline Info & Tech